Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 18 |
| Active Pipeline (Recruiting Now) | 5 (3) |
| Completed vs Stopped Early | 10 / 1 (5.6%) |
| Median Closed Actual Enrollment | 47 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality | 4 |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong | 4 |
| Peking University People's Hospital | Beijing, Beijing Municipality | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04807348 | Chiglitazar Added to Metformin for Type 2 Diabetes | Phase III | COMPLETED |
| NCT05193916 | A Phase II Clinical Trial of Chiglitazar for NASH | Phase II | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Chipscreen Biosciences Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.